Carboplatin-induced severe hypersensitivity reaction: Role of IgE-dependent basophil activation and FcεRI

Cancer Science

Volumn 105, Issue 11, 2014, Pages 1472-1479

  Iwamoto, Takuya ^a,b   Hirai, Hiroyuki ^c   Yamaguchi, Nozomi ^c   Kobayashi, Natsuki ^b   Sugimoto, Hiroko ^a   Tabata, Tsutomu ^b   Okuda, Masahiro ^a,b  

^a MIE UNIVERSITY HOSPITAL   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c BML   (Japan)

Author keywords

Basophil; Biological markers; Carboplatin; Hypersensitivity reaction; Immunoglobulin E

Indexed keywords

ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; ENPP3 PROTEIN, HUMAN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; INORGANIC PYROPHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE; WORTMANNIN;

AGED; ANTAGONISTS AND INHIBITORS; BASOPHIL; COMPLICATION; DRUG EFFECTS; DRUG HYPERSENSITIVITY; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BASOPHILS; CARBOPLATIN; DRUG HYPERSENSITIVITY; FEMALE; GENE EXPRESSION; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOPHENOTYPING; MIDDLE AGED; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; RECEPTORS, IGE;

EID: 84911389394     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12538     Document Type: Article

References (32)

1. Markman M, Kennedy A, Webster K et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17: 1141-5.
2. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010; 2010: 1-11.
3. Sugimoto H, Iwamoto T, Murashima Y, Tabata T, Sagawa N, Okuda M. Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. Cancer Chemother Pharmacol 2011; 67: 415-9.
4. Pagani M, Venemalm L, Bonnadona P, Vescovi PP, Botelho C, Cernadas JR. An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem. Jpn J Clin Oncol 2012; 42: 347-50.
5. Patil SU, Long AA, Ling M et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol 2012; 129: 443-7.
6. Vyas N, Yiannakis D, Turner A, Sewell GJ. Occupational exposure to anti-cancer drugs: a review of effects of new technology. J Oncol Pharm Pract 2013; 20: 278-87.
7. Boumiza R, Debard AL, Monneret G. The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy 2005; 3: 9.
8. MacGlashan D Jr. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy 2010; 40: 1365-77.
9. Hennersdorf F, Florian S, Jakob A et al. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res 2005; 15: 325-35.
10. Hino M, Shimojo N, Ochiai H et al. Expression of CD203c on basophils as a marker of immunoglobulin E-mediated (L)-asparaginase allergy. Leuk Lymphoma 2014; 55: 92-6.
11. Abuaf N, Rostane H, Rajoely B et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. Clin Exp Allergy 2008; 38: 921-8.
12. Iwamoto T, Yuta A, Tabata T et al. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull 2012; 35: 1487-95.
13. Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, Oxaliplatin-, and Cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 2013; 1: 494-500.
14. Sampson HA. Anaphylaxis and emergency treatment. Pediatrics 2003; 111: 1601-8.
15. Aranda A, Mayorga C, Ariza A et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy 2011; 66: 247-54.
16. Tanaka A, Tanaka T, Suzuki H, Ishii K, Kameyoshi Y, Hide M. Semi-purification of the immunoglobulin E-sweat antigen acting on mast cells and basophils in atopic dermatitis. Exp Dermatol 2006; 15: 283-90.
17. Suzuki H, Yanase Y, Tsutsui T, Ishii K, Hiragun T, Hide M. Applying surface plasmon resonance to monitor the IgE-mediated activation of human basophils. Allergol Int 2008; 57: 347-58.
18. Takai T, Takahashi K, Akagawa-Chihara M et al. Production of humanized antibody against human high-affinity IgE receptor in a serum-free culture of CHO cells, and purification of the Fab fragments. Biosci Biotechnol Biochem 2001; 65: 1082-9.
19. Cassard L, Jonsson F, Arnaud S, Daeron M. Fcgamma receptors inhibit mouse and human basophil activation. J Immunol 2012; 189: 2995-3006.
20. Li X, Baskin JG, Mangan EK et al. The unique cytoplasmic domain of human FcgammaRIIIA regulates receptor-mediated function. J Immunol 2012; 189: 4284-94.
21. Jonsson F, Mancardi DA, Zhao W et al. Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood 2012; 119: 2533-44.
22. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90.
23. Kumar S, Verma AK, Das M, Dwivedi PD. Molecular mechanisms of IgE mediated food allergy. Int Immunopharmacol 2012; 13: 432-9.
24. Viardot-Helmer A, Ott H, Sauer I, Merk HF. Basophil activation test as in vitro assay for cisplatin allergy. Hautarzt 2008; 59: 883-4.
25. Ra C, Jouvin MH, Blank U, Kinet JP. A macrophage Fc gamma receptor and the mast cell receptor for IgE share an identical subunit. Nature 1989; 341: 752-4.
26. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991; 9: 457-92.
27. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP. Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 1998; 8: 517-29.
28. Hartman ML, Lin SY, Jouvin MH, Kinet JP. Role of the extracellular domain of Fc epsilon RI alpha in intracellular processing and surface expression of the high affinity receptor for IgE Fc epsilon RI. Mol Immunol 2008; 45: 2307-11.
29. Lin H, Boesel KM, Griffith DT et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
30. MacGlashan DW Jr, Savage JH, Wood RA, Saini SS. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol 2012; 130: 1130-5.e5.
31. MacGlashan DW Jr. IgE-dependent signaling as a therapeutic target for allergies. Trends Pharmacol Sci 2012; 33: 502-9.
32. Gastaminza G, de la Borbolla JM, Goikoetxea MJ et al. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 2011; 21: 108-12.